Evolus Inc (EOLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Evolus Inc (EOLS) has a cash flow conversion efficiency ratio of 0.510x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.67 Million) by net assets ($-28.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Evolus Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Evolus Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Evolus Inc carry for a breakdown of total debt and financial obligations.
Evolus Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evolus Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aspen Aerogels Inc
NYSE:ASPN
|
0.049x |
|
Global Partner Acquisition II Corp
NASDAQ:GPAC
|
0.297x |
|
Kustur Kusadasi Turizm Endustrisi AS
IS:KSTUR
|
0.056x |
|
Globus Spirits Limited
NSE:GLOBUSSPR
|
0.260x |
|
Bali Towerindo Sentra Tbk
JK:BALI
|
0.048x |
|
Ive Group Ltd
AU:IGL
|
0.263x |
|
Jiangxi Changyun Co Ltd
SHG:600561
|
0.057x |
|
Taiwan Hopax Chemsistry MFG Co Ltd
TWO:6509
|
0.067x |
Annual Cash Flow Conversion Efficiency for Evolus Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Evolus Inc from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Evolus Inc (EOLS) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $5.52 Million | $-18.00 Million | -3.260x | -298.29% |
| 2023-12-31 | $-20.69 Million | $-34.01 Million | 1.644x | +135.81% |
| 2022-12-31 | $18.50 Million | $-84.91 Million | -4.590x | -1025.61% |
| 2021-12-31 | $81.88 Million | $-33.39 Million | -0.408x | -151.41% |
| 2020-12-31 | $-72.96 Million | $-57.87 Million | 0.793x | +167.49% |
| 2019-12-31 | $79.46 Million | $-93.38 Million | -1.175x | -286.39% |
| 2018-12-31 | $84.38 Million | $-25.67 Million | -0.304x | -276.28% |
| 2017-12-31 | $-75.54 Million | $-13.04 Million | 0.173x | -90.76% |
| 2016-12-31 | $-7.11 Million | $-13.27 Million | 1.867x | +161.59% |
| 2015-12-31 | $12.00 Million | $-36.38 Million | -3.031x | -- |
About Evolus Inc
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels.… Read more